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Summary Expression of pS2, an oestrogen-regulated gene, has been associated with a good short-term prognosis and response to
endocrine therapy. The aim of this study was to determine whether expression of mRNA for the pS2 gene in breast cancer could contribute
useful information on disease behaviour and survival at medium-term follow-up. Northern blotting was used to detect pS2 messenger
ribonucleic acid (mRNA) in the primary tumour tissue from each of 90 patients with breast cancer. Axillary node status was established by
sampling or clearance, oestrogen receptor concentration by enzyme immunosorbant assay and follow-up was continued for at least 6 years
or until death. At 83 months mean follow-up, 29 of 90 (32%) patients had recurrent disease and, of these, 18 (20%) had died from breast
cancer. pS2 mRNA expression, present in 26 of 90 (29%) cancers, was associated with freedom from disease recurrence (P = 0.026) and
was significantly associated with survival at a minimum of 6 years follow-up (P < 0.001). Pathological node status and tumour size were also
significantly associated with disease recurrence (P < 0.001 and P = 0.002 respectively) and inversely with survival (P < 0.001 and P < 0.001
respectively). After multiple Cox regression analysis, pS2 expression was still a significant predictor of recurrence (but not survival) after
adjusting for node status and tumour size; oestrogen receptor was an independent predictor of survival. The combination of node status and
pS2 expression discriminated patients with particularly good prognosis (node negative, pS2 positive: no mortality at 6 years) or poor
prognosis (node positive, pS2 negative; 41% mortality at 6 years). Evaluation of pS2 expression in breast cancer at diagnosis may provide
additional useful prognostic information to conventional staging.
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The detection of pS2 expression in response to an oestrogenic
stimulus in breast cancer cells (Masiakowski et al, 1982) - an
effect that can be antagonized by tamoxifen - led to speculation
that pS2 could be an oestrogen-regulated gene of clinical impor-
tance. The pS2 gene (also known as BCEI, pNR-2, Md2) encodes
a 600-base mRNA (Masiakowski et al, 1982), which is translated
to a cysteine-rich protein with structural similarities to insulin-like
growth factors I and II (Rio et al, 1987; Stack et al, 1988). The
clinical interest in pS2 is the result of an association with
oestrogen receptor expression and with other conventional
markers of good prognosis (Rio et al, 1987; Stack et al, 1988;
Schwartz et al, 1991; Predine et al, 1992; Thompson et al, 1993;
Detre et al, 1994; Foekens etal, 1994; Speiseretal, 1994; Gibert et
al, 1996; Tutschek et al, 1996). pS2 expression is associated with
good prognosis in female -but not in male -patients at short-term
follow-up (Foekens etal, 1990; Schwartz et al, 1991; Predine etal,
1992; Gion et al, 1993; Kardas et al, 1993; Thompson et al, 1993;
Foekens et al, 1994; Speiser et al, 1994). Conversely, pS2-negative
patients have a significantly shorter relapse-free survival (Gion et
al, 1993; Foekens et al, 1994; Speiser et al, 1994; Schmidt et al,
1996) and overall survival (Gion et al, 1993; Speiser et al, 1994).
pS2 also predicts a subsequent response to hormone manipulation
as first-line therapy and on disease relapse (Henry et al, 1988,
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1990, 1991; Schwartz et al 1991; Soubeyran et al, 1996). Thus, the
detection ofpS2 expression in breast cancers may define a subset
of cancers with functional oestrogen receptors and hence patients
with agood prognosis who are more likely to respond to endocrine
manipulation.
The aim of this study was to determine whether pS2 gene
mRNA expression could contribute useful information on disease
behaviour and survival after a minimum of6 years (medium term)
follow-up.
PATIENTS AND METHODS
Ninety female patients with primary, previously untreated, histo-
logically proven, invasive breast cancer (mean age 56 years, range
30-78 years) underwent surgery for breast cancer. The 2-year
follow-up on a subgroup ofthese women forms part of a previous
report (Thompson et al, 1993). Patients with impalpable disease or
small tumours (when insufficient material was available for study)
were excluded from the study. Fifty-six women were post-
menopausal.
The tumour size on the resected specimen was measured as less
than 2 cm (pTl) in nine patients, 2-4.9 cm (pT2) in 51 patients or
greater than 5 cm (pT3) in 30 patients. Pathological axillary node
status (based on 2-25 nodes per patient) was determined by axil-
lary node sampling or clearance, with 46 of90 patients node posi-
tive and 44 node negative at the time of diagnosis. The histology
of the tumours was invasive ductal cancer of no special type (80
cancers), lobular breast cancer (seven) or special type (three). The
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Figure 1 pS2 mRNA expression in breast cancers, breast cancer cell lines
and reduction mammoplasty tissue. Northern blot autoradiographs probed
sequentially with p82 (0.6-kb mRNA, upper panel) and actin (1.8-kb mRNA,
internal control for loading, lower panel). a, Breast cancer, node positive, no
disease recurrence; b, breast cancer, node positive, no disease recurrence;
c, breast cancer, node negative, no disease recurrence; d, reduction
mammoplasty tissue; e, breast cancer cell line MDA MB 231 (oestrogen
receptor 0 fmol mg-1 protein); f, breast cancer cell line MCF 7 (oestrogen
receptor 120 fmol mg-' protein); g, breast cancer cell line T 47 D
(oestrogen receptor 40 fmol mg-' protein); h, breast cancer, node positive,
disease recurrence; i, breast cancer, node positive, disease recurrence;
j, breast cancer, node negative, disease recurrence
1.0
0.9
a)
._!
ca
0
._
0 ae a._
0.8
0.7
0.6
a1)
0)
0
0
0) s,
U,
C
0
0.I
0
0~
0.9
0.8
0.7
0.6
0.5
-1--
-LI
-LI
__
I__,
0.4
0 20 40 60 80 100
Time since diagnosis (months)
Figure 3 pS2 mRNA expression related to disease recurrence. Breast
cancer recurrence against time since diagnosis (in months) for patients with
pS2 mRNA expression in the primary cancer (-) and patients with no pS2
mRNA in the cancer (--- -), demonstrating a significant association between
pS2 mRNA expression (P< 0.026) and freedom from disease recurrence
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Figure 2 pS2 mRNA expression and survival in breast cancer. Patient
survival against time since diagnosis (in months) for patients with pS2 mRNA
expression in the primary cancer (-) and patients with no pS2 mRNA in the
cancer --- -), demonstrating a significant association between pS2 mRNA
expression (P< 0.001) and survival
oestrogen receptor content of the tumours was measured using an
enzyme immunosorbant assay (ER-EIA, Abbott Laboratories,
North Chicago, IL, USA) and expressed in fmol mg-' protein.
Tumour oestrogen receptor concentrations of20 fmol mg-' protein
or more was considered oestrogen receptor moderate or rich
(Anderson et al, 1989). Tumour grade and progesterone receptor
status was not assessed, in keeping with ourclinical andlaboratory
practice at that time.
In addition to surgical treatment, adjuvant therapy was adminis-
tered to 79 ofthe 90 women: 66 received 20 mg oftamoxifen for a
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Figure 4 Axillary node metastasis and prognosis in breast cancer. Patient
survival against time since diagnosis (in months) for patients subdivided into
axillary node negative (...), one to three axillary nodes containing tumour
--- -) orfour or more axillary nodes involved with tumour (-)
minimum of 5 years, 11 CMF and two underwent surgical
oophorectomy. Clinical and radiological follow-up (including
annual mammography) were continued for at least 6 years or until
death; follow-up ranged from 5 to 98 months with a mean follow-
up of 83 months. Total RNA was extracted from snap-frozen
tumour tissue using the lithium chloride-urea method, and pS2
expression was determined using the Northern blot technique,
with a cDNA probe (Masaikowski et al, 1982) used to detect pS2
messenger ribonucleic acid (mRNA) and actin (Minty et al, 1981)
as an internal control for RNA loading (Thompson et al, 1993).
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measurement, log oestrogen receptor concentration, oestrogen
receptor status (low vs moderate/rich) or menopausal status were
associated with recurrence ofdisease or with survival.
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pS2 mRNA expression was detected in 26 of 90 (29%) breast
0.7 - 1 cancers, six of ten reduction mammoplasty specimens and MCF7
0. and T47D but not the MDA MB 231 cell line (Figure 1). Fifty-one
0.6 oestrogen receptor poor. pS2 mRNA expression was associated
with oestrogen receptor concentrations of 20 or greater fmol mg-'
0.5 protein (chi-square 5.8, P = 0.015, 1 d.f., 95% confidence limits
for oestrogen receptor 1.24-12.3). There was no association
between pS2 expression and node status, tumour size or
menopausal status. At a mean follow-up of 84 months, 29 of 90
20 40 60 80 100 (32%) patients had developed recurrent disease and 18 of 90
Time since diagnosis (months) (20%) of these had died from breast cancer. All 26 patients with
Figure 5 Axillary node metastases and disease-free interval. Disease pS2 mRNA expression in the tumour at diagnosis were alive. On
recurrence plotted against time since diagnosis (in months) for patients univariate analysis, pS2 mRNA expression was significantly asso-
subdivided into axillary node negative ( ...), one to three axillary nodes ciated with survival (P < 0.001) (Figure 2) and with disease-
containing tumour (---) or four or more axillary nodes involved with free interval (P = 0.026) (Figure 3). Taking the clinically useful
tumour (-)
cut-off of 20 fmol mg-' protein to discriminate between oestrogen
receptor-poor (< 20) and oestrogen receptor-moderate/rich (. 20)
tumours, or using oestrogen receptor as a continuous variable, or
Autoradiographs of the probed Northern blots were examined for as the log ofoestrogen receptor, oestrogen receptor expression was
tumour tissue from the 90 patients with primary breast cancer, ten not associated with survival or disease-free interval by univariate
patients who had undergone reduction mammoplasty and three analysis.
breast cancer cell lines: MCF-7, T47D and MDA MB 231. Axillary node metastasis, detected in 6 of 90 (51%) patients at
The chi-square test was used to compare pS2 mRNA expression diagnosis, was significantly associated both with poor prognosis
and oestrogen receptor protein in the tumours and to compare (P < 0.001) (Figure 4) and with shorter disease-free interval
recurrence and death rates at 6 years. Cox proportional hazards (P < 0.001) (Figure 5). Tumour size, measured by the pathologist
regression and multiple Cox regression were used to test whether on the resected specimen, was also significantly associated with
pS2 mRNA expression, node status, tumour size on pathology recurrence (P < 0.001) and survival (P = 0.003).
Table 1 Multiple Cox regression analysis of clinical and pathological parameters related to disease recurrence and survival in breast cancer
P-value
Factor Recurrence Survival
Univariate Multivariate Univariate Multivariate
Node metastasis <0.001 <0.001 0.001 <0.001
Tumour size < 0.001 0.002 0.003 < 0.001
pS2 0.026 0.020 < 0.001 0.92
Oestrogen receptor 0.90 0.52 0.10 0.001
Menopausal status 0.95 0.11 0.82 0.08
Table 2 Recurrence and survival by node status and pS2 mRNA expression.
Node negative Node positive
pS2 mRNA+ pS2 mRNA- pS2 mRNA+ pS2 mRNA- Total
Alive and well 13 27 10 11 61
Recurrent disease 1 0 2 8 11
Dead 0 5 0 13 18
Total 14 32 12 32
pS2 mRNA+, pS2 mRNA positive; pS2 mRNA-, pS2mRNA negative.
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By multiple Cox regression (Table 1), node status and tumour
size both remained independently significant for both recurrence
and survival; pS2 expression was still a significant predictor of
recurrence after adjusting for both these variables, but was not a
predictor for mortality. Oestrogen receptor status became indepen-
dently predictive of mortality (but not disease recurrence) after
adjusting for nodes and size. The combination of node status and
pS2 expression (Table 2) defined patients with particularly good
prognosis (node negative, pS2 positive; no mortality at 5 years) or
poor prognosis (node positive, pS2 negative; 41% mortality at 5
years). When the cancer did not express pS2 mRNA, patients who
were node positive were significantly more likely (P < 0.001) to
develop disease recurrence than patients who were node negative.
DISCUSSION
This study examined pS2 mRNA expression in 90 breast cancers
and related pS2 expression to clinical and pathological parameters
and to disease behaviour at a minimum follow-up of6 years.
pS2 expression was detected in 29% of the breast cancers
studied, which is within the range (22-58%) for mRNA detection
in breast cancer reported by others (Rio et al, 1987; Stack et al,
1988; Skilton et al, 1989; Henry et al, 1990; Zaretsky et al, 1990;
Hahnel et al, 1991; Delvenne et al, 1992; Wysocki et al, 1994) and
similar to the range of 27-68% ofbreast cancers that express pS2
protein (Foekens et al, 1990; Henry et al, 1991; Schwartz et al,
1991; Walker et al, 1995; Tutschek et al, 1996). The more recent
development of reverse transcription polymerase chain reaction
(RT-PCR), which may be a more sensitive method to detect pS2,
allows both the detection and quantification ofpS2 mRNA expres-
sion (Carr et al, 1995). It is unclear whether improved sensitivity
would effect the prognostic value ofpS2 mRNA.
pS2 expression was significantly related to oestrogen receptor
protein expression as expected for an oestrogen-regulated protein
(Rio et al, 1987; Stack et al, 1988; Skilton et al, 1989; Henry et al,
1991; Schwartz et al, 1991; Predine et al, 1992; Thompson et al,
1993; Detre et al, 1994; Foekens et al, 1994; Speiser et al, 1994;
Stonelake et al, 1994; Walker et al, 1995; Gibert et al, 1996;
Tutschek et al, 1996) and we have confirmed the observations of
others that pS2 expression (whether measured as mRNA or
protein) is not significantly associated with tumour size or node
status (Foekens et al, 1990; Schwartz et al, 1991; Delvenne et al,
1992; Gion et al, 1993).
We have demonstrated that, at medium-term (6 year minimum,
mean 83 months) follow-up, pS2 expression remains associated
with good prognosis (Foekens et al, 1990; Schwartz et al, 1991;
Predine et al, 1992; Thompson et al, 1993; Gion et al, 1993;
Foekens et al, 1994; Speiser et al, 1994; Schmidt et al, 1996) in
contrast to one other study ofpS2 mRNA with a shorter follow-up
(Wysocki et al, 1994). Although our study, like that ofSpeiser et al
(1994), failed to identify pS2 as an independent prognostic factor
for survival (which had been suggested by Gion et al, 1993;
Foekens et al, 1994), oestrogen receptor protein was associated
with survival after adjusting for node status and tumour size. As
expected, axillary node status (based on the pathological examina-
tion of surgically resected axillary lymph nodes) and tumour size
were significantly associated with disease recurrence and survival
both on univariate analysis and multivariate analysis.
The most important clinical implication of this study is the
confirmation that pS2 expression has a discriminant effect for
better prognosis in both axillary lymph node-positive (Foekens et
al, 1990; Kausitz et al, 1994) and node-negative patients
(Stonelake et al, 1994). Furthermore, the data presented here
suggest that a combination ofaxillary node status and pS2 expres-
sion measured at the time of diagnosis can define patients at high
and low risk ofdeath for medium-term follow-up.
As pS2 expression is a good indicator of endocrine responsive-
ness both in the primary cancer and on relapse (Henry et al, 1988;
Ramm et al, 1988; Skilton et al, 1989; Schwartz et al, 1991;
Westley and May, 1991; Coradini et al, 1996; Soubeyran et al,
1996), the detection of pS2 expression in the primary cancer,
whether at the mRNA or the protein level, may be useful both as
prognostic information and as a guide to therapeutic intervention.
In this study, patients with tumours that were oestrogen receptor
moderate/rich at diagnosis (therefore including the tumours that
express pS2) were treated with tamoxifen. Thus, as changes in pS2
protein expression have been demonstrated during tamoxifen
therapy (Wilsher et al, 1996), it is possible that the apparent
survival advantage at 5 years for the patients with pS2 mRNA
detected in the tumour may be attributable to the effect of tamox-
ifen therapy mediated via pS2.
The usefulness ofpS2 has been taken one step further in clinical
practice; pS2 expression can be used to guide the likely response
to tamoxifen therapy in patients with recurrent breast cancer
(Foekens et al, 1994). While pS2 expression by Northern blotting
may not be suitable for routine pS2 analysis, pS2 measured by
immunohistochemical staining (Wilson et al, 1994) or competitive
reverse transcription polymerase chain reaction (Carr et al, 1995)
on fine-needle aspirates of breast cancer has been used to select
patients over the age of 70 years for tamoxifen therapy. pS2
expression in breast cancer tissue is useful in itself as a marker
of probable hormonal response to endocrine manipulation. This
study has demonstrated that pS2 mRNA expression also provides
useful prognostic information in addition to that provided by axil-
lary node status when oestrogen receptor expression may be of
limited value. pS2 should now be considered for routine clinical
measurement as aresponse indicator and prognostic marker along-
side oestrogen receptor protein.
ACKNOWLEDGEMENTS
The authors thank Dr Wilma Jack and Mrs Ruby Wood for assis-
tance in collecting follow-up data, the Sarah Percy Fund and
Scottish Hospitals Endowments Research Trust (Grant SHERT
868) for financial support and Professor P Chambon for permis-
sion to use the pS2 probe.
REFERENCES
Anderson EDC, Forrest APM, Levack PA, Chetty U and Hawkins RA (1989)
Response to endocrine manipulation and oestrogen receptor concentration in
large operable primary breast cancer. BrJ Cancer60: 223-226
Carr M, May FEB, Lennard TWJ and Westley BR (1995) Determination of
oestrogen responsiveness ofbreast cancer by competitive reverse transcription
polymerase chain reaction. BrJ Cancer 72: 1427-1434
Coradini D, Biganzoli E, Boracchi P, Martelli G and Di Fronzo G (1996) Predictive
role of steroid receptors pS2 and Cathepsin D on the outcome ofelderly breast
cancer patients. Br Can Res Treat 41: 249
Delvenne CG, Winkler-Gol RA, Piccart MJ, Hustin J, Michaux D, Leclerecq G,
Nogaret JM and Autier P (1992) Expression ofc-erbB2, TGF-beta 1 and pS2
genes in primary human breast cancers. EurJ Cancer 28: 700-705
Detre S, King N, Salter S, MacLennan K, McKinna JA and Dowsett M (1994)
Immunohistochemical and biochemical analysis ofthe oestrogen regulated
C CancerResearch Campaign 1998 British Journal ofCancer (1998) 77(3), 492-496496 AM Thompson etal
protein pS2, and its relation with oestrogen receptor and progesterone receptor
in breast cancer. J Clin Pathol 47: 240-244
Foekens JA, Rio M-C, Seguin P, Putten WLJ, Van Fauque I, Nap M, Kiljn JGM and
Chambon P (1990) Prediction ofrelapse and survival in breast cancer patients
by pS2 protein status. CancerRes 50: 3832-3837
Foekens JA, Portengen H, Look MP, van Putten WLJ, Thirion B, Bontenbal M and
Kiljn JGM (1994) Relationship ofpS2 with response to tamoxifen therapy in
patients with recurrent breast cancer. BrJ Cancer70: 1217-1223
Gibert OD, Machuca I, Sebastian MA, Rosel P and Navarro MA (1996) pS2 is a
useful predictor ofregression in tamoxifen therapy. Med Clin 107: 90-92
Gion M, Mione R, Pappagallo GL, Gatti C, Nascimben 0, Bari M, Leon AE,
Vinante 0 and Bruscagnin G (1993) pS2 in breast cancer - alternative or
complementary tool to steroid receptor status? Evaluation of446 cases. BrJ
Cancer 68: 374-379
Hahnel E, Joyce R, Sterrett C, Harvey I and Hahnel R (1991) Detection ofestradiol-
induced messenger RNA (pS2) in uninvolved breast tissue from mastectomies
for breast cancer. Br CancerRes Treat 20: 167-176
Henry JA, Nicholson S, Farndon JR, Westley BR and May FEB (1988)
Measurement ofoestrogen receptor mRNA levels in human breast tumours.
BrJ Cancer58: 600-605
Henry JA, Nicholson S, Hennessy C, Lennard TWJ, May FEB and Westley BR
(1990) Expression ofthe oestrogen regulated pNR-2 mRNA in human breast
cancer: relation to oestrogen receptor mRNA levels and response to tamoxifen
therapy. BrJ Cancer61: 32-38
Henry JA; Piggott NH, Mallick UK, Nicholson S, Farndon JR, Westley BR and May
FEB (1991) pNR-2/pS2 immunohistochemical staining in breast cancer:
correlation with prognostic factors and endocrine response. BrJCancer 63:
615-622
Kardas I, Seitz G, Limon J, Niezabitowski A, Rys J, Theisinger B, Welter C and Blin
N (1993) Retrospective analysis ofprognostic significance ofthe estrogen-
inducible pS2 gene in male breast cancer. Cancer72: 1652-1656
Kausitz J, Kuliffay P, Pecen L, Eben K and Puterova B (1994) Correlation of
cytosolic concentrations ofER, PS2, Cath-D, TPS, TK and cAMP in primary
breast carcinomas. Neoplasma 41: 331-336
Masiakowski P, Breathnach R, Bloch I, Gannon F, Krust A and Chambon P (1982)
Cloning ofcDNA sequences ofhormone-regulated genes from the MCF-7
human breast cancer cell line. NucleicAcids Res 10: 7895-7903
Minty A, Caravatti M, Robert B, Cohen A, Daubas P, Weydert A, Gros F and
Buckingham ME (1981) Mouse actin messenger RNAs. JBiol Chem 256:
1008-1014
Predine I, Spyratos F, Prud-Homme JF, Andrieu C, Hacene K, Brunet M,
Pallud C and Milgrom E (1992) Enzyme-linked immunosorbent assay ofpS2 in
breast cancers, benign tumours, and normal breast tissues. Cancer 69:
2116-2123
Ramm S, Robert N, Pappas CA and Tamura H (1988) Defective estrogen receptors
in human mammary cancers: their significance in defining hormone
dependence. JNatl Cancer Inst80: 756-761
Rio MC, Bellocq JP, Gairard B, Rasmussen UB, Krust A, Koehl C, Calderoli H,
SchiffV, Renaud R and Chambon P (1987) Specific expression ofthe pS2 gene
in subclasses ofbreast cancers in comparison with expression ofthe estrogen
and progesterone receptors and the oncogene ERBB2. Proc NatlAcad Sci USA
84: 9243-9247
Schmidt R, Sorger D, Walter F, Schonfelder M and Preiss R (1996) pS2 protein,
EGFR and Cathepsin-D in association with established prognostic factors in
early recurrence ofbreast cancer. Onkologie 19: 176-180
Schwartz LH, Koerner FC, Edgerton SM, Sawicka JM, Rio MC, Bellocq JP,
Chambon P and Thor AD (1991) pS2 expression and response to hormonal
therapy in patients with advanced breast cancer. Cancer Res 51: 624-628
Skilton RA, Luqmani YA, McClelland RA and Coombes RC (1989) Characterisation
ofa messenger RNA selectively expressed in human breast cancer. BrJ Cancer
60: 168-175
Soubeyran I, Quenel N, Mauric L, Durand M, Bonichon F and Coindre J-M (1996)
Variation ofhormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast
carcinomas under tamoxifen: a study of74 cases. BrJ Cancer73: 735-743
Speiser P, Stoizlechner S, Haider K, Heinzi H, Jakesz R, Pecherstorfer M, Rosen H,
Sevelda P and Zeilliger R (1994) pS2 protein status fails to be an independent
prognostic factor in an average breast cancer population. AnticancerRes 14:
2125-2130
Stack G, Kumar V, Green S, Ponglikitmongkol M, Berry M, Rio MC, Nunez AM,
Roberts M, Bellocq P, Gairard B, Renaud R and Chambon P (1988) Structure
and function ofthe pS2 gene and estrogen receptor in human breast cancer
cells. In Breast Cancer: Cellular andMolecularBiology, Lippmann ME and
Dickson RB. (eds), pp. 185-206. Kluwer: Boston
Stonelake PS, Baker PG, Gillespie WM, Dunn JA, Spooner D, Morrison JM,
Bundred NJ, Oates GD, Lee MJ and Neoptolemos JP (1994) Steroid receptors,
p52 and cathepsin D in early clinically node-negative breast cancer. EurJ
Cancer30: 5-11
Thompson AM, Hawkins RA, Elton RA, Steel CM, Chetty U and Carter DC (1993)
pS2 is an independent factor ofgood prognosis in primary breast cancer. BrJ
Cancer 68: 93-96
Tutschek B, Niederacher D, Caminada MC, Gohring UJ, Schaol A, Schnurch HG,
Beckman MW and Bender HG (1996) pS2 protein detected by
immunohistochemistry in archival primary breast cancer - prognostic value and
long term follow-up in 219 patients. Oncol Rep 3: 759-764
Walker RA, Rajakariar R and Dookeran KA (1995) Comparison ofpS2 and
cathepsin D in primary breast carcinomas. The Breast4: 137-142
Westley B and May FEB (1991) Estrogen-related messenger RNAs in human breast
cancer cells. Cancer Treat Res 53: 259-271
Willsher PW, Gee JMW, Blamey RW, Nicolson RI and Robertson JFR (1996)
Changes in ER, PgR and pS2 protein during tamoxifen therapy for primary
breast cancer. Br CancerRes Treat 41: 288
Wilson YG, Rhodes M, Ibrahim NBN, Padfield CJH and Cawthorn SJ (1994)
Immunocytochemical staining ofps2 protein in fine-needle aspirate from breast
cancer is an accurate guide to response to tamoxifen in patients aged over 70
years. BrJSurg 81: 1155-1158
Wysocki SJ, Iacopetta BJ and Ingram DM (1994) Prognostic significance ofpS2
mRNA in breast cancer. EurJ Cancer30A: 1882-1884
Zaretsky JZ, Weiss M, Tsarfaty I, Hareuveni M, Wreschner DH and Keydar I (1990)
Expression ofgenes coding for pS2, c-erbB2, estrogen receptor and the H23
breast tumour associated antigen. FEBS Lett 265: 46-50
British Journal ofCancer(1998) 77(3), 492-496 0 CancerResearch Campaign 1998